Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia/Invasive Candidiasis

• Tipo: Artigo em Revista Científica Internacional
• Data: 2013

Autores

Liu, P (Autor) Outra; Ruhnke, M (Autor) Outra; Meersseman, W (Autor) Outra; Paiva, J-A (Autor) FMUP; Kantecki, M (Autor) Outra; Damle, B (Autor) Outra

Revista

Título: Antimicrobial Agents and Chemotherapy

Vol. 57

Páginas: 1672-1676

ISSN: 0066-4804

Editora: American Society for Microbiology

Indexação

ISI Web of Knowledge - 48 Citações

Scopus - 53 Citações

Outras Informações

ID Authenticus: P-005-2BR

DOI: 10.1128/aac.02139-12

Abstract (EN): The pharmacokinetics of intravenous anidulafungin in adult intensive care unit (ICU) patients were assessed in this study and compared with historical data from a general patient population and healthy subjects. Intensive plasma sampling was performed over a dosing interval at steady state from 21 ICU patients with candidemia/invasive candidiasis. All patients received the recommended dosing regimen (a 200-mg loading dose on day 1, followed by a daily 100-mg maintenance dose), except for a 54-year-old 240-kg female patient (who received a daily 150-mg maintenance dose instead). Plasma samples were assayed for anidulafungin using a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters in ICU patients were calculated by a noncompartmental method. With the exclusion of the 240-kg patient, the median (minimum, maximum) age, weight, and body mass index (BMI) of 20 ICU patients were 57 (39, 78) years, 65 (48, 106) kg, and 23.3 (16.2, 33.8) kg/m(2), respectively. The average anidulafungin area under the curve over the 24-hour dosing interval (AUC(0-24)), maximum concentration (C-max), and clearance (CL) in 20 ICU patients were 92.7 mg.h/liter, 7.7 mg/liter, and 1.3 liters/h, respectively. The exposure in the 240-kg patient at a daily 150-mg dose was within the range observed in ICU patients overall. The average AUC(0-24) and C-max in the general patient population and healthy subjects were 110.3 and 105.9 mg.h/liter and 7.2 and 7.0 mg/liter, respectively. The pharmacokinetics of anidulafungin in ICU patients appeared to be comparable to those in the general patient population and healthy subjects at the same dosing regimen.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 5